Grants for Special district governments - Food and Nutrition

The Food Safety Education Fund grants program, administered by the Michigan Department of Agriculture & Rural Development (MDARD), is designed to enhance food safety throughout Michigan. Funded by assessments on licensed food establishments, the program aligns with a mission to protect public health by providing critical food safety training and education. This initiative directly supports the broader goal of ensuring a safe food supply for all Michigan residents. The foundation's strategic priority is to prevent foodborne illness through proactive education and the empowerment of various stakeholders within the food system. The program primarily targets two key beneficiary groups: Michigan consumers and food service establishment employees, as well as agents of the director who enforce food regulations (e.g., local health department sanitarians and MDARD food safety inspectors). The impact goal is to improve food safety knowledge and practices among these groups, ultimately reducing the incidence of foodborne illnesses. Eligibility is restricted to Michigan governmental and non-profit organizations and entities, ensuring that the grants support organizations deeply embedded in community health and public service. Producers, marketers, processors, and growers are explicitly excluded to maintain the program's focus on education and training. For the 2024-2025 grant cycle, up to $365,600 is available, with a specific allocation of $242,500 for consumer food safety education and $114,100 for food service establishment employees and regulatory agents. This demonstrates a clear prioritization of widespread public education while also fortifying the knowledge base of those directly involved in food handling and enforcement. The grant duration is typically one year, though multi-year proposals are considered on an individual basis, contingent on future funding availability. Proposals should specifically avoid requesting funding for routine or required training, such as HACCP or ServSafe certification, emphasizing a focus on innovative and supplementary educational initiatives. Proposals are evaluated based on several key criteria, including goals and objectives to improve food safety, assessment of statewide need and audience, measurable outcomes, potential for partnering with other organizations, inclusion of matching funds, and opportunities to build upon previously funded projects. These selection criteria reflect the program's theory of change, which posits that strategic partnerships, evidence-based interventions, and quantifiable results are essential for achieving sustainable improvements in food safety. The expected outcomes include a more informed public, better-trained food service professionals, and more effective enforcement of food safety regulations, all contributing to a safer food environment across Michigan.

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization may be submitted to this FOA. This assumes such a change is programmatically permitted for the particular grant. Applications for change of recipient organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of recipient organization may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.

This funding opportunity supports researchers in discovering and validating new targets for developing safe and effective pain treatments with minimal side effects and low addiction risk.

This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build research activities in nonmalignant hematology. This Funding Opportunity Announcement (FOA) is intended to promote innovative research projects in nonmalignant hematology that explore high impact and new directions of inquiry. While each Institute shares interests in nonmalignant hematology research, they also bring different perspectives, thereby expanding the scope of the SHINE II program beyond a single Institute's research mission. This "New Directions in Hematology Research (SHINE-II)" program invites investigator-initiated grant applications for basic or early translational, proof of principle research projects that are tightly focused and directed at validating novel concepts and approaches that promise to advance new pathways for discovery. This program may include clinical research involving human subjects that is directed at understanding disease pathogenesis and prognosis. Research applications submitted under this FOA should be more limited in scope (single aim with sub-aims, as appropriate) and duration (1-3 years) than typical R01 grant applications. The SHINE-II FOA seeks specifically to promote and support new directions of research in their early stages. Applications submitted to this FOA should include preliminary data that support the conceptual basis of the research proposed and the technical approaches to be used. Moreover, while research applications submitted under this FOA are expected to be more limited in scope and shorter in duration than typical R01 applications, achievement of the research objective(s) proposed should validate novel pathways of discovery and provide the basis for future high impact research endeavors. Principal areas of interest for this collaborative FOA include: (1) hematopoietic stem cell biology, (2) lineage fate determinants, (3) aging-related immune dysfunction and lymphocyte biology, (4) myeloid cell biology, and myelopoiesis, (5) platelet biology and dysfunction, (6) erythroid cell biology and erythropoiesis, (7) the molecular biology of heme and hemoglobin, (8) acquired and congenital disorders of red blood cell production and survival leading to chronic anemia or bone marrow failure, (9) and the uptake, utilization, storage, and transport of iron in health and disease. Inquiries to Scientific/Research staff prior to submission of an application to this FOA are strongly encouraged to discuss programmatic relevance and potential time tables for funding (see below, Section VII. Agency Contacts). The limited scope and shorter duration of the SHINE II R01 are not optimal for Early Stage Investigators (ESIs) and New Investigators (NIs), who should contact Scientific/Research staff prior to submission of an application to this FOA.

This Notice of Funding Opportunity (NOFO) seeks to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental biological mechanisms underlying HIV-associated comorbidities, co-infections, and complications relevant to the mission of the NIDDK and advance progress toward preventing or alleviating them.

The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.

The Community Foundation of Southern Wisconsin is accepting applications for its Women’s Fund, a component fund managed by an Advisory Board of community volunteers and staff. The fund's mission aligns with the Foundation's broader goals by providing a permanently endowed funding source to non-profit agencies serving the needs of women and girls in Rock County, while also offering hands-on grant-making and leadership experiences for Fund donors. This initiative directly supports the Foundation's strategic priorities by empowering women and girls and fostering community engagement in philanthropic efforts. The primary beneficiaries of this grant program are women and girls in Rock County, Wisconsin, particularly those facing mental health challenges. The fund aims to address needs such as depression, anxiety, caregiver stress, addictions, work/family stress, isolation, and human trafficking. The impact goals are to improve the mental well-being of this target population through both prevention and response programs. The Foundation's theory of change suggests that investing in girls yields higher returns, impacting women's wages, reproductive choices, and their capacity to raise healthy, educated children who will continue this positive cycle. The program prioritizes proposals from 501(c)(3) charitable Rock County organizations and municipalities. Eligible projects and programs must serve the mental health needs of women and girls, including a wide range of services and interventions. Specific focuses include training programs for targeted audiences, support groups, mentoring programs, and resource identification. The fund strongly encourages collaborations throughout Rock County, emphasizing a community-wide approach to addressing these critical needs. Requests from individuals are explicitly not eligible. Expected outcomes include improved mental health conditions for women and girls in Rock County, increased access to mental health services, and strengthened community resources to support these populations. While specific measurable results are not explicitly detailed in the provided text, the focus on various program types (prevention, response, training, support groups) suggests a commitment to measurable improvements in mental health indicators. The emphasis on community collaborations also implies an expected outcome of a more integrated and effective support system for women and girls in the region.

FDA announces the availability of fiscal year (FY) 2024 funds to support one or more projects to 1) collect antimicrobial use data from diverse animal sectors, including domestic livestock, poultry, companion animals (dogs, cats, and horses), and minor species (e.g., fish, sheep, goats) and 2) contribute to the development of data collection frameworks, including providing data and expertise as resources and a public-private partnership frameworks are established. This grant will support the continued advancement of FDA;apos;s initiatives to support antimicrobial stewardship in veterinary settings. It will also support the National Action Plan objectives to engage the animal health community and relevant stakeholders to advance strategies intended to improve understanding of antimicrobial use and foster antimicrobial stewardship in animal agriculture.

This funding opportunity supports researchers in planning high-risk, multi-center clinical studies focused on kidney, digestive, diabetes, and metabolic disorders, helping them develop essential protocols and administrative frameworks before conducting the actual trials.

This funding opportunity provides financial support for researchers developing innovative, non-opioid treatments for various types of pain, with a focus on early-stage studies and collaboration with underrepresented populations.

The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemically pure form; 2) assessment of the biological activity of each stereo chemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs.

The GOODS Program is a grant opportunity provided by Greater Good Charities. It aims to distribute food, essential supplies, clothing, housewares, toys, and more to pets and people in need across the world. The program helps various constituents including pets (homeless and owned), families facing economic hardships, unhoused populations, military veterans, domestic violence survivors, victims of disasters, and displaced persons. The GOODS Program works by sourcing and managing excess, re-branded, and short-dated food and supplies from donors such as manufacturers, distributors, and retailers. These products are then made available to qualified distribution groups called Ambassadors who ensure they reach the organizations in need known as Recipients. The program operates through a sustainable hub and spoke model similar to a food bank where goods are donated but costs are covered by handling fees and donations. To apply as a Recipient organization, interested parties can locate the nearest Ambassador on the program's website and apply directly through their website. For general inquiries or to inquire about grants and services, individuals can contact Greater Good Charities through their website or send checks to their designated address in Seattle, WA.

This funding opportunity supports predoctoral students in dual-degree programs at institutions without NIH-funded training programs, helping them pursue research and clinical training to become future physician-scientists.

This funding opportunity supports the development of innovative tools and technologies aimed at advancing research and treatment in kidney, urologic, and hematologic diseases, encouraging projects that push scientific boundaries and have broad applications beyond individual research interests.

The Resilient Food Systems Infrastructure (RFSI) program, funded by the USDA, allocates approximately $2 million for infrastructure grants to Vermont businesses and organizations aiming to strengthen local and regional food systems. The grants support projects that improve the aggregation, distribution, manufacturing, processing, storing, transporting, and wholesaling of Vermont food products. This track encourages development of Vermont value-added products and promotes fair wages and job creation. A 50% match is required, which can be reduced to 25% for historically underserved farmers. Grants range from $100,000 to $500,000 and are available from fall 2024 through February 2027.

The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement. The proposed work directly supports the U.S. FDAs stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities. In addition to the work outlined above, the award recipient will assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multidisciplinary and multi-level research designed to develop and/or test interventions to optimize care of persons with Type 2 diabetes from populations with health/health care disparities concordant with evidence-based guidelines. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations. Proposed projects would be expected to develop and/or test patient-centered strategies, which in addition to optimal glycemic control, would aim at completing other recommended guidelines (e.g., annual eye/foot and urine albumin exam, optimal blood pressure control, intake of ACEIs or ARBs/statin/aspirin and influenza/pneumonia vaccines).

This Notice of Funding Opportunity (NOFO) invites applications from institutions/organizations that propose to establish a Research Resource Center (RRC) for the NIDDK Nutrition Obesity Research Centers (NORC) Program. The NORC Program consists of eleven Centers across the nation that support and enhance the national research effort in nutrition and obesity through cutting-edge basic, clinical, translational, and health disparities research in nutrition science and obesity. In collaboration with the existing NORC program, the RRC will (1) provide administrative support for the entire NORC Program, (2) establish and curate a NORC Program website and centralized repository of research resources , (3) implement a multipronged approach to support and grow the early-to-midcareer research workforce, including individuals from diverse backgrounds, with a goal of maximizing national outreach and impact, (4) administer and manage a NORC Opportunity Program to address gaps and promote collaboration, and (5) manage a Pilot and Feasibility Program.This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.Research Objectives Utilizing the ACTC, the goal of this FOA is to invite research grant applications that provide clinical testing (Phases Ib-III) of promising pharmacological and/or non-pharmacological interventions for cognitive and neuropsychiatric symptoms in individuals with AD or other aging-related dementias across the spectrum from pre-symptomatic to more severe stages of disease. Working with the ACTC is a cooperative venture between the applicant, the NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. Potential applicants are strongly encouraged to contact NIA Scientific/Research Contacts (see Agency Contacts, Section VII) and the ACTC study team in order to discuss the feasibility of conducting the proposed trial through the ACTC infrastructure before considering an application. The ACTC infrastructure is welcoming of the following: Academic and industry applicants Pharmacological and non-pharmacological interventions Applications are encouraged that propose the following: Testing candidate therapeutic compounds against novel therapeutic targets Testing repurposed drugs derived from data-driven approaches, including candidates coming from NIA's translational bioinformatics FOA (PAR-17-032) Logistical guidance: Potential applicants undergo initial vetting of proposed study by the ACTC protocol evaluation committee and final review by the steering committee. Applicants should contact the ACTC study team at least 5 months prior to their desired NIA submission cycle. Contact details and more information may be found at actcinfo.org. Applications should anticipate using a centralized IRB. Applicants should be aware of the data and resource sharing requirements. The use of common contract language is strongly encouraged. Note, the ACTC infrastructure is not appropriate for: Single site clinical trials Routine Phase Ia first-in-human Clinical trials funded from this FOA will be implemented through the ACTC. The clinical trials approved for funding will develop their final protocols in conjunction with the ACTC. All ACTC sites will have the option to request participation and will be selected based on their capabilities specific to the individual protocols. Investigators are strongly encouraged to collect blood and other biosamples for future genomic and other 'omic' analyses aimed at interrogating treatment responsiveness and examining predictors of decline and progression. See Section VIII. Other Information for award authorities and regulations.